BiotechTube
Synvivia

Synvivia

Cambridge, United States· Est.
synvivia.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

Synvivia is a private, preclinical-stage biotech leveraging a novel platform of engineered molecules to reprogram cells for therapeutic benefit in metabolic disorders. Its core technology is designed to address the root cause of diseases like diabetes by modifying cell behavior, positioning it in the cutting-edge field of cell therapy. As a young company, it is likely in the research and development phase, building its scientific foundation and seeking venture funding to advance its programs. The long-term vision is to translate this platform into transformative, off-the-shelf cell therapies for patients with significant unmet medical needs.

MetabolicDiabetes

Technology Platform

Engineers molecules to reprogram cells for therapeutic application in metabolic diseases.

Funding History

1
Total raised:$3.5M
Seed$3.5M

Opportunities

The global diabetes market is vast and underserved by curative therapies, presenting a multi-billion dollar opportunity for a successful cell-based treatment.
The platform's potential to be applied to other metabolic disorders like obesity and NASH significantly expands the addressable market.
Success could position the company as an attractive acquisition target for large pharma seeking next-generation metabolic disease assets.

Risk Factors

High scientific risk associated with the novel and complex approach of cell reprogramming, including potential safety issues like off-target effects.
As a preclinical, private company, it faces significant financial risk and dependence on future fundraising in a competitive capital environment.
The regulatory pathway for such an advanced therapy is uncertain and could be lengthy and expensive.

Competitive Landscape

Synvivia competes in a crowded and advanced field of diabetes cell therapy, facing companies like Vertex (with its stem cell-derived islet cell program VX-880 in Phase 1/2) and Sernova (with its cell pouch device). It also competes broadly with gene therapy and other regenerative medicine approaches for metabolic disease. Its differentiation hinges on the specific mechanism and potential advantages of its 'reprogramming molecule' platform.

More companies in Biologics / Biosimilars →More companies in United States →